A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Prestige BioPharma
- 12 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
- 31 Aug 2018 Biomarkers information updated
- 03 Apr 2018 Planned End Date changed from 1 Jun 2020 to 1 Feb 2021.